J Natsume1, N Maeda2, K Itomi3, H Kidokoro2, N Ishihara2, H Takada2, A Okumura4, T Kubota5, K Miura2, K Aso6, T Morikawa7, K Kato8, T Negoro2, K Watanabe9. 1. From the Departments of Pediatrics (J.N., N.M., H.K., N.I., H.T., K.M., T.N.) junnatsu@med.nagoya-u.ac.jp. 2. From the Departments of Pediatrics (J.N., N.M., H.K., N.I., H.T., K.M., T.N.). 3. Department of Neurology (K.I.), Aichi Children's Health and Medical Center, Obu, Japan. 4. Department of Pediatrics (A.O.), Juntendo University Faculty of Medicine, Tokyo, Japan. 5. Department of Pediatrics (T.K.), Anjo Kosei Hospital, Anjo, Japan. 6. Department of Pediatrics (K.A.), Aichi Prefecture Medical Welfare Center of Aoitori, Nagoya, Japan. 7. Morikawa Clinic (T.M.), Nagoya, Japan. 8. Radiological and Medical Laboratory Sciences (K.K.), Nagoya University Graduate School of Medicine, Nagoya, Japan. 9. Faculty of Health and Medical Sciences (K.W.), Aichi Shukutoku University, Nagakute, Japan.
Abstract
BACKGROUND AND PURPOSE: Developmental and seizure outcomes in patients with cryptogenic West syndrome are variable. Our aim was to clarify the relationship between FDG-PET findings in infancy and long-term seizure and developmental outcome in cryptogenic West syndrome. MATERIALS AND METHODS: From 1991 to 1999, we prospectively performed FDG-PET from the onset of cryptogenic West syndrome in 27 patients. PET was performed at onset and at 10 months of age. In 2012, we evaluated the educational status, psychomotor development, and seizure outcome in 23 of the 27 patients (13-22 years of age). The correlation between PET findings and outcome was evaluated. RESULTS: At onset, PET showed hypometabolism in 13 patients (57%). The second PET after the initial treatment revealed cortical hypometabolism in 7 patients (30%). While hypometabolism at onset disappeared on the second PET in 9 patients, it was newly revealed in 3 patients on the second PET. In 2012, seven patients had persistent or recurrent seizures. Eight patients had intellectual impairment. The first PET did not correlate with seizure or developmental outcome. Five of 7 patients (71%) with hypometabolism seen on the second PET had persistent or recurrent seizures, while 14 of 16 (88%) patients with normal findings on the second PET were free of seizures. Five of 7 patients (71%) showing hypometabolism on the second PET had intellectual impairment. Thirteen of 16 (81%) patients with normal findings on the second PET showed normal intelligence. A significant correlation was found between the second PET and long-term seizure (P = .01) or developmental outcome (P = .03). CONCLUSIONS: Cortical hypometabolism is not permanent; it changes with clinical symptoms. Hypometabolism after initial treatment predicts long-term seizures and poor developmental outcome.
BACKGROUND AND PURPOSE: Developmental and seizure outcomes in patients with cryptogenic West syndrome are variable. Our aim was to clarify the relationship between FDG-PET findings in infancy and long-term seizure and developmental outcome in cryptogenic West syndrome. MATERIALS AND METHODS: From 1991 to 1999, we prospectively performed FDG-PET from the onset of cryptogenic West syndrome in 27 patients. PET was performed at onset and at 10 months of age. In 2012, we evaluated the educational status, psychomotor development, and seizure outcome in 23 of the 27 patients (13-22 years of age). The correlation between PET findings and outcome was evaluated. RESULTS: At onset, PET showed hypometabolism in 13 patients (57%). The second PET after the initial treatment revealed cortical hypometabolism in 7 patients (30%). While hypometabolism at onset disappeared on the second PET in 9 patients, it was newly revealed in 3 patients on the second PET. In 2012, seven patients had persistent or recurrent seizures. Eight patients had intellectual impairment. The first PET did not correlate with seizure or developmental outcome. Five of 7 patients (71%) with hypometabolism seen on the second PET had persistent or recurrent seizures, while 14 of 16 (88%) patients with normal findings on the second PET were free of seizures. Five of 7 patients (71%) showing hypometabolism on the second PET had intellectual impairment. Thirteen of 16 (81%) patients with normal findings on the second PET showed normal intelligence. A significant correlation was found between the second PET and long-term seizure (P = .01) or developmental outcome (P = .03). CONCLUSIONS:Cortical hypometabolism is not permanent; it changes with clinical symptoms. Hypometabolism after initial treatment predicts long-term seizures and poor developmental outcome.
Authors: L Metsähonkala; E Gaily; H Rantala; E Salmi; L Valanne; T Aärimaa; E Liukkonen; I Holopainen; M-L Granström; M Erkinjuntti; T Grönroos; M Sillanpää Journal: Neurology Date: 2002-06-11 Impact factor: 9.910